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1. Abbreviations 
 
  AOM acute otitis media 
CC clonal complex 
CFU colony-forming unit 
CLI clindamycin 
CLR clarithromycin 
CLSI Clinical and Laboratory Standards Institute 
CPS polysaccharide capsule 
CTX cefotaxime 
IPD invasive pneumococcal disease 
IPM imipenem 
LVX levofloxacin 
MBA microtiter biofilm assay 
MIC minimum inhibitory concentration 
MLST multi-locus sequence typing 
NCC null-capsule clade  
NESp nonencapsulated Streptococcus pneumoniae 
OD optical density 
PBP penicillin-binding protein 
PCG penicillin G 
PCR polymerase chain reaction 
PCV pneumococcal conjugate vaccine 
PFGE pulse-field gel electrophoresis 
PRSP penicillin-resistant Streptococcus pneumoniae  
PspK pneumococcal surface protein K 
QRDR quinolone-resistant determination region 
SEM scanning electron microscopy  
ST sequence type 
TFLX tosufloxacin 
THYB Todd-Hewitt broth plus 0.5% yeast extract  
TSA trypticase soy agar 
VAN vancomycin  
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2. Abstract 
 
With the aim of controlling pediatric pneumococcal diseases, oral broad-spectrum 
antibiotics for use against drug-resistant Streptococcus pneumoniae and 
pneumococcal conjugate vaccine (PCV) were recently introduced in Japan. 
Tosufloxacin (TFLX) is a fluoroquinolone antimicrobial agent. TFLX granules 
for children were initially released in Japan in 2010 to treat otitis media and 
pneumonia caused by drug-resistant bacteria, e.g. penicillin-resistant S. 
pneumoniae and beta-lactamase-negative, ampicillin-resistant Haemophilus 
influenzae. The evolution of bacterial resistance since TFLX approval is not well 
known. On the other hand, the prevalence of nonencapsulated S. pneumoniae 
(NESp) has increased with the introduction of PCV in children; however, the 
bacteriological characteristics of NESp have not been sufficiently clarified. 
To clarify the influence of S. pneumoniae  derived from children after the 
introduction of new oral fluoroquinolone and PCV, two studies were conducted. 
In the first study, to clarify the influence of quinolones administered to children 
since their approval, we examined the resistance mechanism of TFLX-resistant S. 
pneumoniae isolated from pediatric patients as well as patient clinical 
characteristics. TFLX-resistant strains (MIC ≥2 mg/L) were detected among 
clinical isolates of S. pneumoniae derived from children (≤15 years old) between 
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2010 and 2014. These strains were characterized based on quinolone-resistance 
determination regions (QRDRs), i.e. gyrA, gyrB, parC, and parE. In addition, the 
antimicrobial susceptibility, serotype, and multilocus sequence type of the strains 
were determined, pulsed-field gel electrophoresis was performed, and patients 
clinical characteristics based on medical records were assessed for cases with 
underling TFLX-resistant strains. Among 1,168 S. pneumoniae isolates, two 
TFLX-resistant strains were detected from respiratory specimens obtained from 
pediatric patients with frequent exposure to TFLX. Both strains had mutations in 
the QRDRs of gyrA and parC. One case exhibited gradual changes in the QRDR 
during the clinical course.  
In the second study, NESp strains isolated from the nasopharyngeal carriage of 
children from four nursery schools in Japan were analyzed for molecular type, 
antibiotic susceptibility, and biofilm productivity. A total of 152 putative S. 
pneumoniae strains were identified by optochin-susceptibility analysis, of which 
21 were not serotypeable by slide agglutination, quellung reaction, or multiplex 
PCR. Among these 21 strains, three were lytA-negative and, therefore, not S. 
pneumoniae. The remaining 18 strains were positive for lytA, ply, pspK, and bile 
solubility and were therefore confirmed as NESp. Therefore, the isolation rate of 
NESp in the S. pneumoniae strains in this study was 12.0% (18/149). Molecular-
typing analyses classified five strains as two existing sequence types (STs; 
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ST7502 and ST7786), and 13 strains formed four novel STs. Horizontal spread 
was suspected, because strains with the same ST were often isolated from the 
same nursery school. The NESp isolates were generally susceptible to most 
antimicrobials, with the exception of macrolides; however, all isolates possessed 
more than one abnormal penicillin-binding protein gene. Furthermore, NESp 
strains were more effective than encapsulated counterparts at forming biofilms, 
which showed obvious differences in morphology.  
To our knowledge, this is the first study of quinolone-resistant S. pneumoniae 
isolated from children, including clinical data, in Japan. These data may help 
prevent increases in infections of quinolone-resistant S. pneumoniae in children; 
specifically, the results emphasize the importance of administering 
fluoroquinolones only in appropriate cases. Furthermore, the data of NESp 
indicated that NESp strains should be continuously monitored as emerging 
respiratory pathogens. 
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3. Introduction 
Streptococcus pneumoniae colonizes the upper respiratory tract and can be a 
major causal pathogen of otitis media, pneumonia, and invasive diseases, such as 
sepsis and meningitis, in children. With the aim of controlling pediatric 
pneumococcal diseases, oral broad-spectrum antibiotics against drug-resistant S. 
pneumoniae and pneumococcal conjugate vaccine were recently introduced in 
Japan. 
Penicillin-nonsusceptible S. pneumoniae have increased rapidly since around 
1990 and are a major problem in many countries [1-3]. Recently, pediatric 
respiratory infections due to macrolide-resistant Mycoplasma pneumoniae and 
beta-lactamase non-producing ampicillin-resistant Haemophilus influenzae have 
become critical issues in Japan [4,5]. Accordingly, oral fluoroquinolone 
tosufloxacin (TFLX) was initially released for children in January 2010. Since its 
introduction, many pediatricians and otolaryngologists prescribed TFLX owing 
to its clinical effectiveness, good compliance based on a twice-daily dosage, and 
relatively pleasant taste. Frequent use of TFLX may lead to an increased risk of 
drug-resistant bacteria. Therefore, the development of quinolone-resistant S. 
pneumoniae in children is a concern in Japan. A decrease in TFLX susceptibility 
has been observed for S. pneumoniae derived from children with community-
acquired pneumonia [6]. However, the precise frequency of quinolone-resistant S. 
9 
 
pneumoniae in children in Japan is unknown.  
Most of S. pneumoniae strains have polysaccharide capsule (CPS) and more than 
95 different CPS types have been identified. The heptavalent pneumococcal 
conjugate vaccine (PCV7) was introduced in Japan in February 2010 and switched 
to 13-valent vaccine (PCV13) in November 2013 for prevention of pediatric 
pneumococcal diseases. The increased use of the PCV in infants has decreased 
the total number of invasive pneumococcal disease (IPD) cases; however, the 
percentage of those caused by non-vaccine serotypes has increased dramatically, 
suggesting that non-vaccine serotype IPDs have replaced vaccine serotype IPDs 
[7-9]. A similar change has also been observed in S. pneumoniae isolated from 
nasopharyngeal carriage [10]. Most S. pneumoniae are regarded as harboring a 
CPS; however, the existence of nonencapsulated S. pneumoniae (NESp) was 
recently reported.  
NESp is mainly classified into two types based on CPS presence. The first group 
harbors a non-functional capsular polysaccharide synthesis (cps) locus located 
between the glucan 1,6-a-glucosidase gene (dexB) and the oligopeptide ABC-
transporter gene (aliA). Previous studies found that cps becomes non-functional 
because of mutations in the initiating glucose phosphate transferase (cpsE; also 
identified as wchA) [11,12]. These strains are nontypeable with the quellung 
reaction using pneumococcal antisera, but can be typed by polymerase chain 
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reaction (PCR). The second group comprises true NESp that completely lacks the 
cps locus, which is replaced with other gene sequences. The lack of the capsular 
polysaccharide biosynthesis gene (cpsA; also identified as wzg) identifies this 
group, which is divided into four clades based on the presence of three genes 
encoding pneumococcal surface protein K (pspK; also identified as nspA) and two 
oligopeptide-binding lipoproteins (aliB-like homologs called aliC and aliD). 
These four groups are named null-capsule clade (NCC)1, NCC2, NCC3, and 
NCC4 [12-14]. NCC1 harbors the gene encoding the virulence factor pspK, which 
possesses basic structure and size variations and is negative for aliC and aliD [13-
16]. NCC2 is aliC- and aliD-positive, but negative for pspK, and NCC3 is aliD-
positive, but negative for aliC and pspK. NCC4 contains only transposable 
elements in the cps locus. 
For the clinical aspects of NESp, a recent study reported that the NESp rate was 
12.5% for streptococcal carriage in children [17]. Because PCVs do not provide 
immunity against NESp, the appearance of NESp might be related to the wide use 
of PCVs for children. Additionally, NESp pathogenicity has not been clarified, 
with previous reports indicating that NESp rarely cause IPD [7]. On the other 
hand, NESp induces non-invasive diseases, such as otitis media, sinusitis, and 
conjunctivitis [17-20], and it is expected that respiratory infections caused by 
NESp will increase along with increases in the NESp carriage rate in children. 
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Therefore, understanding NESp pathogenicity and drug sensitivity is critically 
important to formulate effective treatment strategies.  
To clarify the influence of S. pneumoniae  derived from children after the 
introduction of new oral fluoroquinolone and PCV, two studies were conducted. 
In the first study, we analyzed the gene sequences of quinolone resistance-
determining regions (QRDRs) in TFLX-resistant S. pneumoniae isolated from 
pediatric patients to determine the mechanism of TFLX resistance. Additionally, 
we analyzed S. pneumoniae isolates obtained from a single patient over time to 
elucidate the dynamic process by which TFLX resistance is acquired. The 
frequent use of oral quinolones by children led to changes in the QRDR and an 
increase in the minimum inhibitory concentration (MIC) of quinolone in S. 
pneumoniae. 
In the second study, we characterized NESp strains by multi-locus sequence 
typing (MLST) and assessed strains for cps and pspK expression. Additionally, 
we examined drug sensitivity, mutations in genes encoding penicillin-binding 
proteins (PBPs), and the presence of macrolide- and quinolone-resistance genes. 
Moreover, we determined differences in biofilm formation between typeable S. 
pneumoniae and NESp strains by microtiter biofilm assays (MBAs) and scanning 
electron microscopy (SEM). 
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4. Chapter1. Quinolone-resistant strains in Streptococcus pneumoniae 
isolated from pediatric patients 
 
4.1 Materials and methods 
 
4.1.1 S. pneumoniae strains 
In total, 1,168 clinical isolates of S. pneumoniae derived from children (≤15 years 
old) were isolated at the Chiba Children’s Hospital between 2010 and 2014. The 
specimen categories for S. pneumoniae strains are shown in Table 1. Among these 
isolates, two TFLX-resistant strains (MIC ≥2 mg/L) were analyzed; one strain, 
referred to as strain 1, was isolated in 2010 and the other strain, referred to as 
strain 2, was isolated in 2014. Six pneumococcal strains isolated from a single 
patient who had TFLX-resistant strain 2 were also analyzed (Figure 1). Patient 
characteristics (i.e. age, sex, underlying disease, previous exposure to TFLX, and 
history of pneumococcal conjugate vaccination) were retrospectively analyzed 
based on medical records for patients with a confirmed TFLX-resistant strain. 
Patient names were de-identified. This study was approved by the Chiba 
Children’s Hospital Ethics Committee (approval number 2016-11-31). 
These isolates were stored at -80°C in 10% skim milk until use. Each isolate was 
grown on trypticase soy agar (TSA) with 5% sheep blood (Nippon Becton 
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Dickinson Co. Ltd., Tokyo, Japan) for 24 h at 37°C in 5% CO2. Each isolate was 
identified as S. pneumoniae using an optochin susceptibility test and a bile 
solubility test. PCR assays targeting the lytA gene, which encodes the major 
pneumococcal autolysin (LytA), were also used to identify S. pneumoniae. All 
strains were susceptible to optochin, bile-soluble, and positive for the lytA gene, 
and were therefore identified as S. pneumoniae. 
 
Table 1. Specimen categories of Streptococcus pneumoniae strains 
 
  
J Infect Chemother 2017;23:218–23, Table 1. 
 
Source Strain numbers (%) 
sputum 706 (60.4) 
nasopharynx 217 (18.5) 
nasal discharge 146 (12.5) 
ear discharge/middle ear effusion  33 (2.8) 
pharynx/tonsil/gingiva 20 (1.7) 
blood 19 (1.6) 
eye discharge 12 (1.0) 
cerebrospinal fluid  2 (0.1) 
others 13 (1.1) 
 
total 1,168 (100.0) 
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Figure 1. The drug history for a single patient. 
Grey bars show the episodes of exposure to quinolones. Arrows show the timing of isolation of 
each strain. Between the isolation of 2c and 2, TFLX was prescribed in several episodes. J 
Infect Chemother 2017;23:218–23, Figure 1. 
 
 
4.1.2  Antimicrobial susceptibility testing 
Antimicrobial susceptibility testing was performed using the broth microdilution 
method according to the Clinical and Laboratory Standards Institute (CLSI) 
standard method and the MIC was determined. The MIC breakpoints for TFLX 
were determined in accordance with the recommendations for respiratory 
infections established by the Japanese Society of Chemotherapy [21]. 
 
4.1.3  Capsular serotyping and molecular typing 
 
Serotypes were determined using the slide agglutination reaction with the S. 
pneumoniae antisera ‘Seiken’ set (Denka Seiken, Tokyo, Japan) and the Quellung 
reaction using pneumococcal antisera (Statens Serum Institut, Copenhagen, 
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Denmark). 
Molecular typing was performed by MLST as described by Enright et al. [22]. 
Seven housekeeping genes, i.e. aroE, gdh, gki, recP, spi, xpt, and ddl, were 
amplified by PCR for MLST. The sequencing reaction was carried out using the 
Big Dye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster 
City, CA, USA). The Applied Biosystems 3130xl Genetic Analyzer was used for 
sequencing. Allelic numbers and sequence types (STs) were determined using the 
MLST website (http://spneumoniae.mlst.net/). 
Each isolate was subcultured on TSA with 5% sheep blood (Nippon Becton 
Dickinson) for 24 h at 37°C in 5% CO2. Bacterial genomic DNA was extracted 
from several colonies of each isolate by the boiling method. Extracted DNA was 
stored at -20°C prior to PCR amplification. 
 
4.1.4  Quinolone resistance-determining region (QRDR) sequencing 
 
The QRDRs of gyrA, gyrB, parC, and parE were amplified by PCR. The primers 
for each loci were synthesized as described by Pan et al. and Balsalobere et al. 
[23,24]. The primers are described in Table 2 and were generated using KOD FX 
Neo® (TOYOBO, Osaka, Japan). The sequencing reaction was performed using 
the Big Dye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). 
Sequencing was performed using the Applied Biosystems 3130xl Genetic 
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Analyzer. The sequences were compared with those of wild-type S. pneumoniae 
R6 using data obtained from GenBank (accession number NC-003098). 
 
Table 2. Primers used for QRDR sequencing 
 
J Infect Chemother 2017;23:218–23, Table 2. 
 
4.1.5  Detection of other drug-resistance genes 
Mutations in genes encoding PBPs (i.e. pbp1a, 2x, and 2b), the targets of beta-
lactams, and the presence of mef(A) and erm(B), which are associated with 
resistance to macrolides in S. pneumoniae, were detected by PCR using the 
Penicillin-resistant S. pneumoniae Detection Reagent Kit (Wakunaga 
Pharmaceutical, Osaka, Japan). 
 
4.1.6  Pulse-field gel electrophoresis (PFGE) 
 
Target gene Primer sequence (5′ to 3′) Product 
size (bp) 
References 
gyrA CCGTCGCATTCTCTACGGAATGAATGAATT 380 24 
 GCTCCATTAACCAAAAGGTTTGGAA  24 
gyrB TTCTCCGATTTCCTCATG 458 23 
 AGAAGGGTACGAATGTGG  23 
parC CAAGACCGGGCTTTGCCAGATATTC 406 24 
 TGCTGGCAAGACCGTTGG  23 
parE AAGGCGCGTGATGAGAGC 290 23 
 TCTGCTCCAACACCCGCA  23 
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The clonal relatedness among isolates was determined by PFGE using the 
restriction enzyme SmaI [25]. The DNA fragments were separated on a 1% 
agarose gel. Electrophoresis was performed in 0.5× Tris/borate/EDTA buffer at 6 
V/cm and at 14°C for 20 h with pulse time of 5.3–34.9 s and linear ramping using 
the CHEF-DRIII system (Japan Bio-Rad Laboratories, Inc., Tokyo, Japan). A 
DNA size standard lambda ladder was used as a reference marker. 
 
4.2 Results 
 
4.2.1  Bacteriological analysis and patient clinical characteristics for TFLX-
resistant S. pneumoniae 
 
Two TFLX-resistant strains (isolated in 2010 and 2014) were detected from 1,168 
clinical isolates of S. pneumoniae. Accordingly, the frequency of quinolone-
resistant S. pneumoniae was 0.2%. 
The demographic data and antimicrobial susceptibility profiles of the two TFLX-
resistant strains are summarized in Table 3. Strain 1 was isolated from the gingiva 
of a 7-year-old patient with gingivitis. Strain 2 was isolated from the sputum of a 
3-year-old patient with pneumonia. With respect to strain 1, several normal 
bacterial flora were also cultured from gingiva and S. pneumoniae could not be 
conclusively identified as the causative pathogen. However, for strain 2, S. 
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pneumoniae was predominantly cultured from the sputum compared with normal 
bacterial flora, and was considered the causal pathogen.  
Both strains exhibited sensitivity to penicillin G (PCG), but were resistant to 
macrolides and fluoroquinolones. The MICs of TFLX for the two strains were 
high, i.e. ≥32 and 8 mg/L, respectively, and those of levofloxacin were both 16 
mg/L. The serotype of the two strains was 23F, which is included in PCV7, but 
they exhibited different STs. The two isolates showed different PFGE profiles. 
With respect to clinical background, both cases had an underlying disease and 
were previously prescribed several courses of oral quinolones. The patient who 
had strain 1 was prescribed powdered TFLX tablets prior to the approval of TFLX 
granules for children. TFLX was administered approximately once a month for a 
1-year period when the patient had a fever in an outpatient clinic. For the patient 
who had strain 2, the times at which TFLX was administered are shown in Figure1. 
 
4.2.2  Detection of drug-resistance genes in TFLX-resistant S. pneumoniae 
 
The two strains had mutations in the QRDRs of gyrA and parC. There was a Ser81 
mutation in the GyrA QRDR and Ser79 and Asp83 mutations in the ParC QRDR, 
indicating that both strains had mutations in genes related to tolerance, according 
to previous functional analyses [26-29]. Several mutations other than Ser79 and 
Asp83 were also detected in the ParC QRDR. In ParE, no mutations were 
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observed in strain 1; however, but a mutation was observed at Ile460 in strain 2. 
Neither of the strains had a mutation in GyrB.  
Both strains had mutations in other drug resistance genes, i.e. pbp1a, 2x, and 2b. 
Strain 1 had mef(A) and strain 2 had both erm(B) and mef(A). 
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 Table 3. Demographic data and antimicrobial susceptibility profile of two TFLX-resistant strains 
 
 
a: TFLX, tosufloxacin; LVX, levofloxacin; PCG, penicillin G; CTX, cefotaxime; IPM, imipenem; MIN, minocycline; CLR, clarithromycin; CLI, 
clindamycin; VAN, vancomycin 
b: Mutations in penicillin-binding protein genes (pbp1a, 2x, and 2b), the targets of the beta-lactams 
c: The presence of the mef(A) and erm(B) genes was associated with resistance to macrolides ; +, gene was detected; －, gene was not detected 
d: A mutation in QRDR was associated with resistance to quinolones 
e: Data are displayed in Fig.2. 
J Infect Chemother 2017;23:218–23, Table 3. 
 
 
 
 
  
 
Strain 
No. 
Patient Clinical Information 
Source 
MIC (mg/L)a 
Mutation in PBP 
genesb 
Presence of 
macrolide 
resistant genesc 
Mutation in QRDRd 
Sero 
type 
 
ST 
 
PFGE 
patterne 
 
Age 
(yr) 
Infection 
Previous 
exposure to 
quinolones 
Underlying 
disease 
Vaccination of 
PCV 
 
TFLX 
 
LVX PCG 
 
CTX 
 
 
IPM 
 
MIN 
 
CLR 
 
 
CLI 
 
 
VAN 
 
erm(B) mef(A) ParC ParE GyrA GyrB 
 
1 
 
 
7 
 
 
gingivitis 
 
Yes 
 
congenital 
neutropenia 
 
 
PPSV23 
 
gingiva 
 
≥32 
 
16 
 
 
1 
 
 
0.5 
 
 
0.12 
 
 
4 
 
 
≥16 
 
≥16 
 
0.25 
 
 
pbp1a + 2x+2b 
 
 
－ 
 
 
+ 
 
 
S52G 
 S79Y 
 I81M 
Y82R 
D83N 
N91D 
 
 
none 
 
S81Y 
 
none 
 
23F 
 
 
242 
 
 
 
A 
 
 
2 
 
 
3 
 
 
pneumonia 
 
Yes 
 
West syndrome, 
chronic 
respiratory 
disease 
 
 
PCV7×1 
 
 
sputum 
 
8 
 
 
16 
 
 
0.25 
 
 
0.5 
 
 
＜0.06 
 
 
4 
 
 
≥16 
 
≥16 
 
0.25 
 
 
pbp1a + 2x+2b 
 
 
+ 
 
+ 
 
S52G 
S79F 
N91D 
 
I460V 
 
 
S81F 
 
none 
 
23F 
 
1437 
 
 
B 
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Table 4. Antimicrobial susceptibility profile of isolates from the patient who had strain 2 
 
 
a: TFLX, tosufloxacin; LVX, levofloxacin; PCG, penicillin G; CTX, cefotaxime; IPM, imipenem; MIN, minocycline; CLR, clarithromycin; CLI, 
clindamycin; VAN, vancomycin 
b: Mutations in penicillin-binding protein genes (pbp1a, 2x, and 2b), targets of the beta-lactams 
c: Presence of the mef (A) and erm (B) genes was associated with resistance to macrolides; +, gene was detected; －, gene was not detected 
d: The mutation in QRDR was associated with resistance to quinolones 
e: Data are summarized in Fig.2. 
J Infect Chemother 2017;23:218–23, Table 4. 
 
Strain 
No. 
Patient Age 
Source 
MIC (mg/L)a 
Mutation in PBP 
genesb 
Presence of 
macrolide resistant 
genesc 
Mutation in QRDRd 
Sero 
type 
 
ST 
 
PFGE 
patterne 
 
Yr Mo 
 
TFLX 
 
LVX PCG 
 
CTX 
 
 
IPM 
 
MIN 
 
CLR 
 
 
CLI 
 
 
VAN 
 
erm(B) mef(A) ParC ParE GyrA GyrB 
 
2a  
 
 
1 
 
 
11 
 
sputum 
 
＜0.12  
 
 
1  
 
 
2  
 
 
1  
 
 
0.25  
 
 
0.12  
 
 
≥16 
 
≥16 
 
0.5  
 
 
pbp1a + 2x+2b 
 
 
－ 
 
 
+ 
 
 
none 
 
I460V 
 
 
none 
 
none 
 
15A  
 
 
63 
 
 
 
C  
 
 
2b  
 
 
2 
 
 
5 
 
sputum 
 
0.25  
 
 
2  
 
 
1  
 
 
0.25  
 
 
0.25  
 
 
8  
 
 
≥16 
 
≥16 
 
0.25 
 
 
pbp1a + 2x+2b 
 
 
－  
 
 
+ 
 
A115P  
 
 
I460V 
 
 
none 
 
none 
 
15A 
 
63 
 
 
C  
 
 
2c 
 
2 
 
5 
 
sputum 
 
＜0.12  
 
 
1  
 
 
0.25  
 
 
0.5  
 
 
＜0.06  
  
 
 
8  
 
 
≥16 
 
≥16 
 
0.25  
 
 
pbp1a + 2x+2b  
 
 
+ 
 
+ 
 
none 
 
I460V 
 
 
none 
 
none 
 
23F 
 
1437 
 
 
B  
 
 
2d 
 
2 
 
10 
 
sputum 
 
＜0.12  
 
 
1  
 
 
0.25  
 
 
0.5 
 
0.12  
 
 
8  
 
 
≥16 
 
≥16 
 
0.25  
 
 
pbp1a + 2x+2b  
 
 
+ 
 
+ 
 
none 
 
I460V 
 
 
none 
 
none 
 
23F 
 
1437 
 
 
B  
 
 
2e  
 
 
3 
 
1 
 
sputum 
 
0.25  
 
 
1  
 
 
0.25  
 
 
0.5 
 
＜0.06  
 
 
4  
 
 
≥16 
 
≥16 
 
0.25  
 
 
pbp1a + 2x+2b  
 
 
+ 
 
+ 
 
S52G 
S79F 
N91D  
 
 
I460V 
 
 
none 
 
none 
 
23F 
 
1437 
 
 
B  
 
 
2  
 
 
3 
 
2 
 
sputum 
 
8  
 
 
16  
 
0.25 
 
0.5  
 
 
＜0.06  
 
 
4  
 
 
≥16 
 
≥16 
 
0.25  
 
 
pbp1a + 2x+2b  
 
 
+ 
 
+ 
 
S52G 
S79F 
N91D  
 
 
I460V 
 
 
S81F 
 
none 
 
23F 
 
1437 
 
 
B  
 
 
2f  
 
 
4 
 
1 
 
sputum 
 
＜0.12  
 
 
1  
 
 
0.5  
 
 
0.5 
 
0.12  
 
 
8  
 
 
1  
 
 
＜0.06  
 
 
0.25  
 
 
pbp2x+2b  
 
 
+ 
 
－  
 
 
none 
 
none 
 
none 
 
none 
 
35B  
 
 
7809 
 
D  
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4.2.3  Changes in quinolone-resistance genes of S. pneumoniae isolated 
from a single patient before and after the use of TFLX 
 
In the patient who had strain 1, S. pneumoniae was not previously detected. 
However, in the other patient, S. pneumoniae was detected several times 
before and after the detection of strain 2. Therefore, we analyzed S. 
pneumoniae isolates from the patient that became resistant to TFLX during 
the repeated use of TFLX. Six isolates were obtained before (strain 2a, 2b, 
2c, 2d, and 2e) and after (strain 2f) the initial time of isolation of the TFLX-
resistant strain (strain 2) (Figure 1). Table 4 summarizes the properties of the 
7 isolates, including strain 2. 
In ParC, a mutation was detected in 2b and 2e, in addition to strain 2. Strain 
2b had an Ala115→Pro mutation, and strain 2e had Ser52→Gly, Ser79→Phe, 
and Asn91→Asp in ParC. Strain 2e and 2 had the same mutant ParE 
genotype. In ParE, a mutation was detected in Ile460→Val in strain 2a, 2b, 
2c, 2d, and 2e, in addition to strain 2. No isolates other than strain 2 had a 
mutation in GyrA, and no isolates had a mutation in GyrB.  
Figure 2 shows the PFGE profiles of SmaI restriction digests. In strain 2a 
and 2b, the serotype (15A), ST (ST 63), and PFGE pattern were identical. In 
strain 2c, 2d, 2e, and 2, the serotype (23F) and ST (ST1437) were also 
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identical, and the PFGE patterns were almost identical, except for a one-band 
shift in strain 2e and 2. Strain 2f and strain 1 had a distinct pattern. These 
results show that the particular strain gained quinolone tolerance 
progressively, with changes noted in strain 2a and 2b, as well as strain 2c, 2d, 
2e, and 2. 
 
 
Figure 2. PFGE profiles of SmaI restriction digests. 
M: DNA ladder, Lane1: strain 2a, Lane2: strain 2b, Lane3: strain 2c, Lane 4: strain 2d, 
Lane5: strain 2e, Lane6: strain 2, Lane7: strain 2f, Lane8: strain 1 
J Infect Chemother 2017;23:218–23, Figure 2. 
 
 
4.3 Discussion 
 
TFLX is an oral fluoroquinolone developed by Toyama Chemical Co. Ltd. 
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(Tokyo, Japan) in 1990. The granule form was released for administration to 
children with otitis media or pneumonia in Japan in January 2010. In Japan, 
the use of TFLX for children is recommended only for pneumonia when a 
resistant bacterial infection is suspected and other antimicrobial agents are 
expected to be ineffective. However, TFLX use in Japan for pneumonia in 
children from 0 to 14 years old increased since 2010 and reached 
approximately 30% in 2012 [30]. This increase may be explained by the 
Mycoplasma epidemic caused by the high rate of macrolide-resistant M. 
pneumoniae in Japan from late 2011 to the end of 2012 [31,32] because 
TFLX is clinically effective for the treatment of macrolide-resistant M. 
pneumoniae infections[33]. 
Fluoroquinolone-resistant S. pneumoniae has been reported in adults, for 
whom fluoroquinolones are frequently used to treat a wide range of 
infections [34-37]. In Japan, Yanagihara et al. examined the rate of 
levofloxacin-resistant S. pneumoniae isolated from adults based on 
nationwide surveillance. They estimated that the frequency of resistant 
strains was 1.1% [38]. On the other hand, in children, the frequency of 
fluoroquinolone-resistant or nonsusceptible strains is very low worldwide, 
and only a few studies have examined resistant strains in Taiwan, China, 
Korea, Spain, Belgium, Canada, Russia, and South Africa [39-43]. In Japan, 
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there has been an increase in the MIC of quinolone in S. pneumoniae derived 
from children with community-acquired pneumonia [6]. Some surveillance 
has been performed, but fluoroquinolone-resistant strains have not been 
detected in children [44-46]. In our study, two TFLX-resistant strains were 
detected from 1,168 clinical isolates of S. pneumoniae from pediatric patients. 
The frequency of quinolone-resistant S. pneumoniae was 0.2%. Two patients 
who had quinolone-resistant S. pneumoniae had an underlying disease. 
DNA gyrase and topoisomerase IV, the topoisomerase enzymes targeted by 
the quinolones are each composed of 2 subunits. These subunits are 
designated GyrA and GyrB, which are encoded by gyrA and gyrB, for DNA 
gyrase, and ParC and ParE, which are encoded by parC and parE, for 
topoisomerase IV.  
Resistance to fluoroquinolones in S. pneumoniae usually occurs by a 
stepwise process [47]. Low-level quinolone resistance is caused by 
mutations in the QRDR of one of the subunits and resistance progresses to a 
high level via additional mutations in the QRDR of the second target.  
According to previous reports, topoisomerase IV, mainly ParC, is the 
primary target of trovafloxacin, levofloxacin, norfloxacin, and ciprofloxacin, 
whereas the primary target of gatifloxacin and sparfloxacin is DNA gyrase, 
mainly GyrA [23,48,49]. In this study, the Ser81 mutation in GyrA in both 
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strains, Ser79 mutation in ParC in both strain 1 and 2, and Asp83 mutation 
in ParC in strain 1 were related to tolerance according to the results of 
previous reports [26-29]. The Ile460→Val mutation in ParE was previously 
observed in clinical S. pneumoniae isolates with low-level fluoroquinolone 
resistance [50].  
We also observed changes in the QRDRs within a clone until it gained 
resistance to TFLX. Recently, Chan et al. reported that an S. pneumoniae 
strain isolated from the single patient gained quinolone-resistance during the 
clinical course, but there are no other similar reports [51]. For patients with 
a history of TFLX exposure with a TFLX-resistant strain, the number of 
quinolone-resistant mutations in pneumococcal strains increased over a short 
period of time after TFLX administration. Prescriptions were not provided 
for intravenous quinolone therapy or other quinolone oral medications. The 
successive administration of TFLX initially led to mutations in ParC and 
subsequently in GyrA. After TFLX-resistant strain 2 was detected, the 
patient was treated with cefotaxime and panipenem. This suggests that the 
primary target of TFLX is ParC and the secondary target is GyrA, similar to 
the mechanism of levofloxacin (LVX) resistance. Subsequently, TFLX-
resistant S. pneumoniae was not detected in this patient and another 
quinolone-sensitive serotype was detected. Yokota et al. reported the 
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mutational patterns for quinolone-resistant S. pneumoniae derived from 
adults. Three of the seven quinolone-resistant strains in this study had 
mutations in only GyrA, and not ParC [34]. Several quinolone agents are 
used for adult population. Differences in the usage of quinolone agents 
between adults and children may explain the different mutation patterns 
among age groups. 
We studied fluoroquinolone-resistant strains, but future studies should also 
consider non-susceptible strains. Some sensitive strains have mutations that 
confer resistance, and these strains may easily gain high levels of resistance 
via new mutations. 
The frequency of quinolone-resistant S. pneumoniae is still low, but an 
increase in quinolone use may lead to the emergence of quinolone-resistant 
strains in children. Importantly, to prevent an increase in quinolone-resistant 
strains and to ensure the continued effectiveness of antimicrobial agents in 
children, TFLX should only be used in appropriate cases after antimicrobial 
susceptibility is examined. 
 
5. Chapter2. Molecular typing, antibiotic susceptibility, and biofilm 
production in nonencapsulated S. pneumoniae isolated from children 
 
5.1 Materials and methods 
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5.1.1  S. pneumoniae strains 
 
S. pneumoniae strains were isolated from nasopharyngeal or nasal-swab 
specimens collected from healthy children (0–1-years old) who were newly 
enrolled into four nursery schools in Tokyo, Japan, from October 2012 to 
March 2015. The three nursery schools (A,B, and C) are located in the same 
region, east of Tokyo, and the other one (D) is located in a different region, 
west of Tokyo. The two regions are approximately 30 km apart in straight-
line distance. Parents provided written informed consent, and this study was 
approved by the Ethical Committee of Medical Mycology Research Center, 
Chiba University (Permission No. 2017-12). In total, 11 children were 
targeted in 2012, 39 in 2013, and 37 in 2014. There were no duplicate 
specimens for children enrolled in 2012; however, in 2013 and 2014, 
specimens were collected three times per child per year in general (April-
June, September-November, January-March), the total number of specimens 
was 231. In total, 152 nasopharyngeal carriage isolates were identified by 
optochin-susceptibility test and were stored in 10% skim milk at −80°C until 
analysis. Isolates were propagated on TSA with 5% sheep blood (Nippon 
Becton Dickinson Co. Ltd., Tokyo, Japan) and Todd-Hewitt broth plus 0.5% 
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yeast extract (THYB) for 18 h at 37°C in 5% CO2. Bacterial genomic DNA 
was extracted using a MORA-EXTRACT kit (Kyokuto Pharmaceuticals, 
Tokyo, Japan) and stored at −20°C. Isolates were serotyped by slide 
agglutination reactions with the S. pneumoniae antisera (‘Seiken’ set; Denka 
Seiken, Tokyo, Japan), quellung reactions with pneumococcal antisera 
(Statens Serum Institute, Copenhagen, Denmark), and multiplex PCR [52]. 
Further characterization was performed by bile solubility testing and PCR 
analysis for pneumococcal autolysin (lytA) and the intracellular toxin 
pneumolysin (ply). Polysaccharide cell-wall composition was also assessed 
using ~108 CFU/mL bacterial solution and three rapid antigen-detection kits 
[BinaxNOW pneumococcal antigen kit (Alere, Inc., Waltham, MA, USA); 
RAPIRAN S. pneumoniae and RAPIRAN S. pneumoniae HS (Otsuka 
Pharmaceutical Co. Ltd., Tokyo, Japan)] [53,54]. 
 
5.1.2  Analysis of capsule-phase variants and molecular typing 
 
Presence of cpsA, pspk, aliC, and aliD was determined by PCR amplification 
as previously described [13]. The PCR products were purified with FastGene 
Gel/PCR extraction kit (NIPPON Genetics, Tokyo, Japan) and subjected to 
sequence analysis with a Big Dye Terminator version 3.1 cycle sequencing 
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kit on an Applied Biosystems 3130xl genetic analyzer (Applied Biosystems, 
Foster City, CA, USA). The repeat number of the α-helical repeat structure 
A(E)(E)EEA/TKR/QK contained in pspK was counted, and the pspk 
sequences of all strains were registered in GenBank (accession numbers 
LC258112–LC258129).  
MLST was used to analyze seven housekeeping genes (aroE, gdh, gki, recP, 
spi, xpt, and ddl) by PCR, as previously described [8]. PCR products were 
purified with a FastGene Gel/PCR extraction kit (NIPPON Genetics) and 
subjected to sequence analysis with a Big Dye Terminator version 3.1 cycle 
sequencing kit on an Applied Biosystems 3130xl genetic analyzer (Applied 
Biosystems). Allelic numbers and STs were determined using an MLST 
database (http://spneumoniae.mlst.net/). 
The relatedness of the isolates was determined by constructing a gene tree 
with the neighbor-joining method using MEGA7. 
 
5.1.3  Antimicrobial susceptibility and drug-resistance gene analysis 
 
Antimicrobial-susceptibility testing was performed by broth microdilution 
according to guidelines of the CLSI (for 22 h at 35°C in ambient air) to 
determine MIC. S. pneumoniae ATCC 49619 was used as reference strain for 
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the antibiotic susceptibility test. Three strains were not grown in ambient air, 
but rather under 5% CO2 for the antibiotic susceptibility test. Antimicrobial 
agents employed in this study included PCG, CTX, IPM, CLR, CLI, VAN, 
TFLX, and LVX. The MIC breakpoints for TFLX were determined 
according to recommendations for respiratory infections established by the 
Japanese Society of Chemotherapy [7].  
Mutations in genes encoding PBPs (i.e., pbp1a, pbp2x, and pbp2b) and the 
presence of the macrolide-resistance genes mef(A) and erm(B) were assessed 
by PCR with the penicillin-resistant S. pneumoniae detection reagent kit 
(Wakunaga Pharmaceutical, Osaka, Japan). The QRDRs of gyrase (gyr)A, 
gyrB, parC, and parE were amplified and sequenced as described previously 
in Chapter1. 
 
5.1.4  In vitro biofilm-formation assays 
 
Biofilm formation was assessed by microtiter biofilm assay (MBA). To 
compare NESp strains with encapsulated strains, encapsulated strains were 
isolated from nasopharyngeal carriage and from otorrhea or middle-ear 
effusion with acute otitis media (AOM). Isolates were precultured on TSA in 
5% sheep blood at 37°C in 5% CO2 for 24 h, followed by isolation of single 
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colonies, which were subcultured on the same medium. On the third day, 
cultures were transferred to THYB overnight, and 5 μL of the bacterial 
solution (OD600=0.15-0.65) was added to the wells of 96-well polystyrene 
microplates (As One Corporation, Osaka, Japan) along with 200 μL THYB 
and incubated for 18 h at 37°C under 5% CO2 overnight. Plates were washed 
three times with water, stained with 100 μL of 0.5% crystal violet for 5 min, 
and washed another three times. After drying, 200 μL of 95% ethanol was 
added to each well, and absorbance at 570 nm was measured with SunriseTM 
microplate reader (Tecan Japan Co. Ltd., Kanagawa, Japan). The pspK-
deletion mutant MNZ1131 (derived from wild-type MNZ11 and belonging 
to NCC1) served as a control [13,55]. 
 
5.1.5  Scanning electron microscopy (SEM) 
 
The morphology of biofilms produced by strains 15P200 (NESp strain) and 
15P255 (serotype 24F) was examined by SEM, as previously described [56]. 
A 1 × 1.5 cm polystyrene slide was placed in a culture dish, and cells were 
cultured in THYB for 18 h at 37°C in 5% CO2. Specimens were fixed with 
2.5% glutaraldehyde, post-fixed with 1% OsO4, dehydrated with graded 
ethanol, and transferred with t-butyl alcohol. The samples were freeze-dried 
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with a VFD-21S t-butyl alcohol freeze-drying apparatus (Vacuum Device Co. 
Ltd., Mito, Japan), coated with platinum-palladium with an E-102 ion spatter 
(Hitachi High Technologies, Tokyo, Japan), and observed under an S-3400N 
scanning electron microscope (Hitachi High Technologies, Tokyo, Japan) at 
10 kV. 
 
5.1.6  Statistical analysis 
 
Statistical analysis was performed using JMP software (v7 for Windows; 
https://www.jmp.com/en_us/home.html). The Mann-Whitney U test was 
used to analyze differences among diagnostic groups. 
 
5.2 Results 
 
5.2.1  S. pneumoniae strains 
 
In total, 152 presumptive S. pneumoniae strains were detected in the 
nasopharyngeal carriage isolates by optochin-susceptibility testing. Twenty-
one strains were nontypeable by slide agglutination and quellung reactions, 
and of these, 18 strains were positive for lytA and the intracellular toxin ply 
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expression and bile solubility, indicative of S. pneumoniae. The remaining 
three strains were lytA-negative, and one was also bile-insoluble and, 
therefore, not S. pneumoniae and excluded from further analyses. All 18 
nontypeable strains were confirmed as S. pneumoniae according to three 
rapid antigen-detection kits. 
 
5.2.2  Analysis of capsule-phase variants and molecular typing 
 
Table 5 shows the number of NESp strains among 149 isolates based on the 
nursery school and survey year. Eighteen NESp strains (12.0%) among 149 
isolates were cpsA-negative, and all NESp strains expressed pspK, which 
contained 11 to 33 repeats of the α-helical repeat structure 
A(E)(E)EEA/TKR/QK that contained the novel repeat regions 
AEEEEAKRK and AEEETKQK (Table 6). GenBank accession numbers of 
each strain are shown in Table 6. All NESp strains were negative for both 
aliC and aliD, and based on this finding, all 18 strains were classified as 
NCC1. Additionally, MLST analysis classified the isolates into six STs 
(Table 7). Five strains were classified as either ST7502 or ST7786, whereas 
the remaining 13 strains were classified into four new STs. ST11973, 
ST11974, and ST11975 consisted of known allelic profiles, whereas 
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ST11976 contains the new allelic profile in aroE. ST 7786, ST7502, ST 
11975, and ST11976 belonged to clonal complex (CC) 7786, and ST11974 
belonged to CC1106. CC1106 strains registered in the MLST database were 
all nontypeable or of serotype 14, whereas ST11973 was a singleton. Figure3 
shows the neighbor-joining tree based on the pspk gene and the 
concatenation of seven selected MLST fragments. 
 
Table 5. The number of nonencapsulated strains among 149 nasopharyngeal carriage 
isolates of S. pneumoniae  
 
J Infect Chemother 2019, (in press), Table 1. 
 
  
survey year 
Nursery school(nonencapsulated strains/total) Total 
(%) A B C D 
2012.10～2013.3 0/2 0/0 0/1 0/5 0/8 (0.0) 
2013.4～2014.3 3/11 3/21 0/18 0/21 6/71 (8.4) 
2014.4～2015.3 0/12 2/12 4/10 6/36 12/70 (17.1) 
     18/149 (12.0) 
 
36 
 
 
Table 6. Analysis of capsule phase variants of 18 nonencapsulated strains of S. 
pneumoniae 
 
*, **, *** are isolated from the same child.  
J Infect Chemother 2019, (in press), Table 2. 
  
 
Strain 
bile solubility 
test 
lytA ply cpsA pspK aliC aliD 
repeat number 
of the α-helical 
repeat structure 
GenBank accession no. 
15P223* ＋ ＋ ＋ － ＋ － － 11 LC258112 
15P245* ＋ ＋ ＋ － ＋ － － 33 LC258113 
15P246 ＋ ＋ ＋ － ＋ － － 11 LC258114 
15P232 ＋ ＋ ＋ － ＋ － － 10 LC258115 
15P235 ＋ ＋ ＋ － ＋ － － 10 LC258116 
15P237 ＋ ＋ ＋ － ＋ － － 10 LC258117 
15P286 ＋ ＋ ＋ － ＋ － － 9 LC258118 
15P303 ＋ ＋ ＋ － ＋ － － 9 LC258119 
15P281 ＋ ＋ ＋ － ＋ － － 9 LC258120 
15P291 ＋ ＋ ＋ － ＋ － － 9 LC258121 
15P292 ＋ ＋ ＋ － ＋ － － 9 LC258122 
15P293 ＋ ＋ ＋ － ＋ － － 9 LC258123 
15P192** ＋ ＋ ＋ － ＋ － － 30 LC258124 
15P195*** ＋ ＋ ＋ － ＋ － － 28 LC258125 
15P196 ＋ ＋ ＋ － ＋ － － 28 LC258126 
15P200** ＋ ＋ ＋ － ＋ － － 27 LC258127 
15P203*** ＋ ＋ ＋ － ＋ － － 28 LC258128 
15P205 ＋ ＋ ＋ － ＋ － － 28 LC258129 
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Table 7. Molecular typing of 18 nonencapsulated strains of S. pneumoniae 
 
 
*, **, *** are isolated from the same child.  
J Infect Chemother 2019, (in press), Table 3. 
 
Strain aroE gdh gki recP spi xpt ddl ST 
Nursery 
school 
Detected 
time 
15P223* 8 29 9 15 77 155 31 7786 A 2013.4 
15P245* 8 29 9 15 77 155 31 7786 A 2013.9 
15P246 8 29 9 15 77 155 31 7786 A 2013.9 
15P232 8 29 9 15 77 155 260 11975 B 2013.9 
15P235 8 29 9 15 77 155 260 11975 B 2013.9 
15P237 8 29 9 15 77 155 260 11975 B 2013.9 
15P286 8 29 9 15 77 155 26 7502 B 2014.9 
15P303 8 29 9 15 77 155 26 7502 B 2015.1 
15P281 368 29 9 15 77 155 31 11976 C 2014.9 
15P291 368 29 9 15 77 155 31 11976 C 2015.1 
15P292 368 29 9 15 77 155 31 11976 C 2015.1 
15P293 368 29 9 15 77 155 31 11976 C 2015.1 
15P192** 1 5 4 29 2 3 50 11973 D 2015.1 
15P195*** 8 29 41 15 17 12 31 11974 D 2015.1 
15P196 8 29 41 15 17 12 31 11974 D 2015.1 
15P200** 1 5 4 29 2 3 50 11973 D 2015.3 
15P203*** 8 29 41 15 17 12 31 11974 D 2015.3 
15P205 8 29 41 15 17 12 31 11974 D 2015.3 
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Figure 3. Neighbor-joining tree based on pspK fragments and the concatenation of seven 
selected MLST fragments. (A) Neighbor-joining tree based on pspK fragments. (B) 
Neighbor-joining tree based on the concatenation of seven selected MLST fragments. The 
dendrogram shows the genetic relatedness among nonencapsulated strains. J Infect 
Chemother 2019, (in press), Figure 1. 
  
 
A 
B 
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5.2.3  Antimicrobial-susceptibility testing and detection of drug-
resistance genes 
 
Table 8 shows the results of antimicrobial-susceptibility testing and drug-
resistance genes, as well as MIC values for seven antimicrobial agents. To 
determine MICs according to antimicrobial-susceptibility testing by broth 
microdilution, strains were cultured at 35°C in ambient air, whereas strains 
15P291, 15P292, and 15P293 were grown under 5% CO2.  
Four strains showed reduced susceptibility to PCG (0.12–0.25 mg/L), and 11 
strains showed resistance to CLR (≥1mg/L). The MICs of IPM, TFLX, and 
LVX for all strains each showed susceptibility at 0.06 mg/L, 0.12 mg/L, 
and 2 mg/L, respectively. All strains possessed at least one mutation in a 
PBP, with PBP mutations varying between STs. With respect to macrolide-
resistant gene expression, all strains were positive for erm(B), whereas only 
the two ST7502 strains were mef(A)-positive. For quinolone resistance, the 
QRDRs of DNA gyrase (gyrA and parC) and topoisomerase IV (parC and 
parE) were amplified and sequenced, with multiple mutations detected. Six 
strains harbored a Lys137→Asn mutation in ParC, and 16 strains harbored 
an Ile460→Val mutations in ParE. No strains harbored mutations in gyrA or 
gyrB, and no strains harbored mutations in both the QRDRs of gyrA and 
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parC related to high levels of quinolone resistance. 
 
5.2.4 In vitro biofilm formation 
 
Biofilm formation by the NESp isolates was examined by MBA (Figure 3A). 
The MBA value of MNZ1131 was high, similar to that for other NESp strains. 
Figure 3B shows encapsulated strains isolated from nasopharyngeal carriage, 
and Figure 3C shows encapsulated strains isolated from otorrhea or middle-
ear effusion with AOM. Notably, NESp strains tended to be more effective 
in generating biofilms than encapsulated strains, regardless of the source (p 
< 0.001; Mann-Whitney U test) (Figure 4). 
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Table 8. Antimicrobial susceptibility testing and detection of drug-resistance genes 
 
 
a: Mutations in penicillin-binding protein genes (pbp1a, 2x, and 2b), the targets of the β-
lactams. 
b: The presence of the mef(A) and erm(B) genes was associated with resistance to 
macrolides; +, gene was detected; －, gene was not detected 
c: The mutation in QRDR was associated with resistance to quinolones. 
d: PCG, penicillin G; CTX, cefotaxime; IPM, imipenem; CLR, clarithromycin; CLI, 
clindamycin; VAN, vancomycin; TFLX, tosufloxacin; LVX, levofloxacin 
e: Strains 15P291,15P292, and 15P293 were grown under 5% CO2 because they could 
not grow under aerobic culture.  
*, **, *** are isolated from the same child.  
J Infect Chemother 2019, (in press), Table 4. 
  
 
Strain ST 
Mutation in 
PBP genesa 
Presence of 
macrolide 
resistant genesb 
Mutation in QRDRc 
 
MIC (mg/L)d 
erm(B) mef(A) ParC ParE GyrA GyrB PCG CTX IPM CLR CLI VAN TFLX   LVX   
15P223* 7786 pbp2x ＋ － none I460V none none ≤0.06 0.12 ≤0.06 0.25 ≤0.06 0.25 ≤0.12 1 
15P245* 7786 pbp2x ＋ － none I460V none none ≤0.06 0.12 ≤0.06 0.12 ≤0.06 0.25 ≤0.12 0.5 
15P246 7786 pbp2x ＋ － none I460V none none ≤0.06 0.12 ≤0.06 0.12 ≤0.06 0.25 ≤0.12 0.5 
15P232 11975 pbp1a + 2x + 2b ＋ － none I460V none none ≤0.06 ≤0.06 ≤0.06 0.12 0.12 ≤0.12 ≤0.12 0.25 
15P235 11975 pbp1a + 2x + 2b ＋ － none I460V none none ≤0.06 ≤0.06 ≤0.06 0.5 8 ≤0.12 ≤0.12 0.5 
15P237 11975 pbp1a + 2x + 2b ＋ － none I460V none none ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.12 ≤0.12 1 
15P286 7502 pbp1a + 2x + 2b ＋ ＋ none I460V none none 0.25 0.12 ≤0.06 >8 >8 0.25 ≤0.12 1 
15P303 7502 pbp1a + 2x + 2b ＋ ＋ none I460V none none 0.12 0.12 ≤0.06 >8 >8 0.25 ≤0.12 1 
15P281 11976 pbp2x ＋ － none I460V none none ≤0.06 ≤0.06 ≤0.06 0.25 ≤0.06 0.25 ≤0.2 0.5 
15P291e 11976 pbp2x ＋ － none I460V none none ≤0.06 0.25 ≤0.06 >8 >8 0.25 ≤0.12 1 
15P292e 11976 pbp2x ＋ － none I460V none none ≤0.06 0.25 ≤0.06 >8 >8 0.50 ≤0.12 1 
15P293e 11976 pbp2x ＋ － none I460V none none ≤0.06 0.12 ≤0.06 >8 >8 0.25 ≤0.12 1 
15P192** 11973 pbp2x ＋ － K137N none none none 0.25 0.25 ≤0.06 2 >8 0.25 ≤0.12 1 
15P195*** 11974 pbp2x + 2b ＋ － K137N I460V none none ≤0.06 0.12 ≤0.06 >8 >8 0.25 ≤0.12 1 
15P196 11974 pbp2x + 2b ＋ － K137N I460V none none ≤0.06 0.25 ≤0.06 >8 >8 0.25 ≤0.12 1 
15P200** 11973 pbp2x ＋ － K137N none none none 0.25 0.25 ≤0.06 1 >8 0.25 ≤0.12 1 
15P203*** 11974 pbp2x + 2b ＋ － K137N I460V none none ≤0.06 0.25 ≤0.06 >8 >8 0.25 ≤0.12 1 
15P205 11974 pbp2x + 2b ＋ － K137N I460V none none ≤0.06 0.12 ≤0.06 8 >8 ≤0.12 ≤0.12 0.25 
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Figure 3. In vitro biofilm formation measured by a microtiter biofilm assay. (A) The 
MBA of NESp strains, (B) encapsulated strains isolated from nasopharyngeal carriage, 
and (C) encapsulated strains isolated from otorrhea or middle-ear effusion with AOM. 
The capsular serotypes are denoted in parenthesis. J Infect Chemother 2019, (in press), 
Figure 1S. 
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Figure 4. In vitro biofilm formation measured by a microtiter biofilm assay.  
Biofilm productivities of NESp strains, encapsulated strains isolated from 
nasopharyngeal carriage, and encapsulated strains isolated from otorrhea or middle- ear 
effusion with acute otitis media. Boxplot shows median and 10th, 25th, 75th, and 90th 
percentiles. Green lines show the average for each group. NESp strains tended to be more 
effective in generating biofilms than encapsulated strains, regardless of the source (*p < 
0.001). J Infect Chemother 2019, (in press), Figure 2. 
  
 
Number 
of strains 
Average biofilm 
formation 
Standard 
deviation 
encapsulated strains (AOM) 21 0.0705 0.0809 
encapsulated strains  
(nasopharyngeal carriage) 
19 0.1419 0.1217 
NESp strains 18 0.7962 0.4898 
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5.2.5  Biofilm morphology analysis by SEM 
 
We compared biofilm formation of the NESp strain with that of the 
encapsulated strain. Figure 5 shows SEM images of the various biofilms. 
Interestingly, NESp strain 15P200 attached to the plate and formed a chain 
and clump, and clustered to form a bacterial mass (Figure 5A–C) along with 
mature biofilm formation (Figure 5C). Conversely, 15P255 (serotype 24F), 
a low-level MBA-encapsulated strain (Figure 3B), failed to form a biofilm 
and existed in single, independent, planktonic form (Figure 5D and E). 
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Figure 5. Visualization of biofilm morphology by SEM. (A–C) Strain 15P200 (NESp) 
was observed attaching to the plate and forming a chain and clump, and biofilms. The 
arrows show the biofilm structure. (D, E) Strain 15P255 (serotype 24F) was not observed 
forming a biofilm, but rather existed as a single, independent, and planktonic entity.  
NESp, nonencapsulated S. pneumoniae; SEM, scanning electron microscopy; J Infect 
Chemother 2019, (in press), Figure 3. 
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5.3 Discussion 
 
To our knowledge, this is the first report of bacterial characterization of 
NESp strains regarding their antibiotic susceptibility, possession of drug-
resistance genes, and biofilm productivity. Nontypeable S. pneumoniae 
strains in AOM or carriage were reported from many countries after the 
introduction of PCV, especially PCV13; however, most reports identified 
nontypeable strains by the quellung reaction, thereby making it unclear 
whether these strains were true NESp. The prevalence of true NESp in the 
nasopharyngeal carriage of children has increased relative to that of 
encapsulated strains following the recent introduction of PCV in Portugal 
[10,57]. PspK-positive NESp was recently isolated from sinus cultures from 
children with chronic adenoiditis undergoing a adenoidectomy in the United 
States [58]. These strains are also found throughout several Asian countries 
and often isolated from the sputum, sinus aspirate, and middle ear [15]. In 
Japan, the rate of IPD caused by NESp is low (~0.2–0.3%) according to a 
population-based surveillance of pediatric IPD [7]. On the other hand, NESp 
was responsible for 4.7% and 9.5% of AOM and acute rhinosinusitis cases 
by S. pneumoniae, respectively [18]. Additionally, NESp was detected in 
12.5% of nasopharyngeal samples from healthy children [18]. 
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Here, the rate of NESp was also 12.0% (18/149) among healthy children in 
nursery school, which was consistent with previous reports [18]. All strains 
were pspK-positive and classified as NCC1, with the prevalence of these 
strains increasing annually in nursery school. The evaluation was difficult 
because the number of specimens was small in 2012; however, in 2013 and 
2014, the total detection rates and the number of nursery schools that 
detected NESp strains clearly increased. There is a possibility that the 
prevalence of NESp strains is not only increasing in nursery schools but also 
in the entire region, and there is concern that it will increase further in the 
future. MLST analysis revealed that 5/18 (27.7%) of isolates were classified 
as either ST7502 or ST7786, which were previously reported in the Japanese 
MLST database [18]; however, these STs have not been identified in studies 
from other countries [13,15,58,59]. Notably, ST groupings tended to 
associate with specific nursery schools, indicative of horizontal spread. 
Furthermore, several strains were isolated from the same children at different 
time points. These data suggested that NESp could be a carriage occurring 
over several months.  
Molecular analysis of pspK demonstrated that the number of canonical repeat 
regions varied from 11 to 33 in our NESp isolates. A(E)EEAKR/QK is an α-
helical structure with a highly charged LPXTG motif and a YPT motif that 
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binds the human polymeric immunoglobulin receptor, which is an 
established epithelial pneumococcal receptor [13,60]. In the present study, 
several strains contained AEEEEAKRK or AEEETKQK in novel repeat 
regions. Previous reports, mostly from Asian countries, indicated that strains 
often harbor from three to 38 repeats [13,15]. Interestingly, repeat variation 
is also observed between isolates belonging to the same ST, as well as 
between subsequent isolations from the same child. It is likely that these 
children might be consistently colonized, suggesting that this region is highly 
subject to genomic insertions or deletions. 
Antimicrobial susceptibilities of NESp in our study indicated that all NESp 
isolates showed susceptibility to IPM and TFX; however, 22.2% (4/18) of 
the strains showed reduced susceptibility to PEN (0.12–0.25 mg/L). 
Furthermore, all NESp strains possessed at least one mutation in a PBP. 
Mutations in pbp1a, pbp2b, and pbp2x play important roles in the 
development of resistance to PEN and cephalosporin by S. pneumoniae. 
Specifically, this includes 9/18 (50.0%) strains harboring mutated pbp2x, 
5/18 (27.8%) strains harboring mutated pbp1a + pbp2x + pbp2b, and 4/18 
(22.2%) strains harboring mutated pbp2x + pbp2b. In terms of macrolide 
resistance, 11/18 (61.1%) strains were clarithromycin-resistant (≥1mg/L). 
Several strains were not grown in ambient air, therefore, these strains were 
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cultured under 5% CO2. A previous study showed that the MICs of 
macrolides and ketolides for S. pneumoniae under CO2 tended to be 1- or 2-
fold dilutions higher than those under ambient air due to lower pH [61]. All 
strains were positive for the macrolide-resistant erm(B) gene. In terms of 
quinolone resistance, 6/18 (33.3%) strains harbored a Lys137→Asn 
mutation in ParC, 16/18 (88.9%) strains harbored an Ile460→Val in ParE, 
and there were no strains with mutations in GyrA or GyrB. Resistance to 
fluoroquinolones in S. pneumoniae usually occurs by a stepwise process [47]. 
Low-level quinolone resistance is caused by mutations in the QRDR of one 
of the subunits, with resistance progressing to a high level via additional 
mutations in the QRDR of the second target. Mutations in Ser81 in GyrA, 
Ser79 in ParC, or Asp83 in ParC are major mutations previously reported in 
quinolone-resistant S. pneumoniae [26]; however, these mutations were not 
found in this study. Mutations at Lys137→Asn in ParC and Ile460→Val in 
ParE are not known to contribute to fluoroquinolone resistance generally, but 
there is a report suggesting that the Lys137→Asn mutation in ParC affects 
the primary step in the development of high-level quinolone resistance 
[62,63]. No strains found in this study harbored mutations in both the 
QRDRs of gyrA and parC.  
The prevalence of penicillin-resistant S. pneumoniae (PRSP) strains, such as 
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serotypes 6B and 19F, decreased after PCV7, whereas serotypes 19A and 
15A increased. After replacement with PCV13, serotype 19A strains 
decreased, but increases were observed in serotype 15A and 35B, which were 
not targeted by PCV13 and became problematic as drug-resistant strains 
[7,64-66]. NESp is also capable of becoming a drug-resistant serotype; 
therefore, it is critical to continue monitoring drug susceptibility in NESp 
strains. 
Because of its simplicity, requiring only the use of basic laboratory materials, 
the microtiter plate assay is widely used as the method for studying biofilm 
formation. This assay tests the ability of bacteria to adhere to the plastic 
surface of a microtiter plate; crystal violet is used to stain the biofilm. 
Findings made by using microtiter plate assays should be confirmed by 
microscopy or another method. SEM is frequently used to observe the 
detailed structure of biofilms at the nanometer-scale level, but live biofilms 
cannot be observed by SEM. Biofilm observation methods employing 
fluorescent imaging methods that use confocal laser scanning microscopy 
and fluorescent protein expression systems have become the mainstream in 
biofilm studies for real time imaging of biofilms. [67] 
There are few studies regarding S. pneumoniae biofilm formation [68-70]; 
however, biofilm production in NESp strains has not been investigated 
52 
 
previously. The presence of capsules hinders biofilm development [69]. 
Consistently, nontypeable H. influenzae strains were more effective at 
generating biofilms than their encapsulated type b counterparts [71]. In the 
present study, NESp strains were more effective at forming biofilms than 
encapsulated strains, independent of the isolation source (e.g., carriage or 
AOM). Moreover, MBA analysis of MNZ1131 (ΔpspK) suggested that the 
presence of pspK did not affect the MBA, which can be an issue with 
encapsulated stains. Furthermore, SEM imaging revealed an obvious 
difference in the biofilms produced by NESp versus capsulated strains. 
Biofilms prevent neutrophil phagocytosis, inhibit the efficacy of 
antimicrobial agents, and lead to refractory infection. NESp represent a 
potential causative agent of chronic/recurrent otitis media, as shown using 
the chinchilla model [72]; therefore, biofilm production by NESp might 
relate to chronic/recurrent otitis media. 
There are several limitations of this study. First, the NESp strains were 
isolated from the nasopharyngeal carriage of healthy children and not 
patients with infections; therefore, the characterized strains might not be 
clinically relevant. Additionally, samples were collected from a limited area, 
irrespective of population, which might limit their widespread application. 
Furthermore, the pathogenicity of the strains such as complement sensitivity 
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was not evaluated. Further studies are needed in order to reveal the 
pathogenicity of NESp. 
In summary, our study identified that the rate of NESp from nasopharyngeal 
carriage in healthy children was >10%. Many NESp strains were detected as 
drug resistant through the presence of genetic mutations, and biofilm 
production was substantially greater than that observed in encapsulated 
strains. These results suggest that infections due to NESp might represent an 
important clinical issue in the near future. Therefore, monitoring and 
investigation of the pathogenicity and drug sensitivity of NESp are extremely 
important for the development of treatment and prevention strategies. 
 
6. Conclusions 
We studied the influence of the introduction of new oral fluoroquinolone 
and PCV for children on S. pneumoniae. 
The frequency of quinolone-resistant S. pneumoniae among children was 
0.2%, still low. However, some sensitive strains with mutations that confer 
resistance may easily gain high levels of resistance via new mutations.  
Therefore, an increase in quinolone use may lead to the emergence of 
quinolone-resistant strains in children. To prevent an increase in quinolone-
resistant strains and to ensure the continued effectiveness of antimicrobial 
agents in children, TFLX should only be administered in appropriate cases 
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after antimicrobial susceptibility is examined.  
On the other hand, the rate of NESp from nasopharyngeal carriage in healthy 
children was >10%. Many NESp strains were detected as drug resistant 
through the presence of genetic mutations, and more effective than 
encapsulated strains at forming biofilms. NESp strains should be further 
studied to reveal the pathogenicity and continuously monitored as emerging 
respiratory pathogens. 
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